C L I N I C A L S T U D Y S U M M A R Y

More documents

Recommendations

Info

151557_GreenLightSummary_B 5/31/07 4:29 PM Page 6G R E E N L I G H TC L I N I C A L S T U D Y S U M M A R YStudy & PublicationKey FindingsPVP Cost ($) TURP Cost ($)TURP/ECONA Clinical Outcomes andCost Analysis ComparingPhotoselective Vaporizationof The Prostate to AlternativeMinimally Invasive Therapiesand Transurethral ProstateResection for the Treatment ofBenign Prostatic HyperplasiaJournal:J of Urology 2006Cost of ProcedureCost: 6 mo.:12 mo.:24 mo.:AUA SS / I-PSS:6 mo.:12 mo.:24 mo.:2,8523,0203,2143,589PVP % decr.(avg. mo. score)73 (5.92)74 (5.80)76 (5.25)3,7484,0304,3314,927TURP % decr.(avg. mo. score)67 (7.35)67 (7.30)66 (7.58)Authors:QMAX (mL):PVP % incr.(avg. mo. score)TURP % incr.(avg. mo. score)M. D. StovskyR.I. GriffithsS.B. Duff6 mo.:12 mo.:24 mo.:188 (24.5)199 (25.4)221 (27.3)124 (19.0)125 (19.1)117 (18.1)n = 10,000(hypothetical cohort)QOL:6 mo.:12 mo.:24 mo.:PVP % incr.(avg. mo. score)81 (0.84)82 (0.82)83 (0.75)TURP % incr.(avg. mo. score)76 (1.06)76 (1.09)73 (1.21)Adverse Events: (Cost of Event):% PVP% TURPIncontinence ($286)33Urinary Tract Infection ($314)56Impotence / ErectileDysfunction ($282)010Dysuria ($183)915Bladder Neck Stenosis /Stricture ($534)37Urinary Retention ($294)65Hematuria ($313)56Re-Operation ($3,889)15
151557_GreenLightSummary_B 5/31/07 4:29 PM Page 7G R E E N L I G H TC L I N I C A L S T U D Y S U M M A R YStudy & PublicationKey Findings(80W Laser)Total Group Group 1tPSA level ≤ 6Group 2tPSA level ≥ 6Impact of prostate-specificantigen level and prostatevolume as predictors ofefficacy in photoselectivevaporization prostatectomy:analysis and results of anongoing prospectivemulticentre study at 3 yearsNumber of PatientsProstate Volume:Mean BaselineVolume mL—54.6 mL87 pts at base80 pts at 1 year59 pts at 2 years31 pts at 3 years48.3 mL52 pts at base48 pts at 1 year24 pts at 2 years16 pts at 3 years83.1 mLJournal:Mean % reductionvia TRUS at 3 years29%26%34%BJU 2006Baseline tPSA, ng/mL:Mean (SD range)3.5 (2.8, 0.1 – 9.8)——Authors:% level reduction17%34%26%A.E. TeT. R. MalloyB.S. SteinJ.C. UlchakerU.O. NseyoM.A. HaiFollow up: 3 yearsNo Catheterization:Length of Catheterizationhrs.: Mean(range)Re-catheterization:AUASI% improvementQMAX: mL/s% Improvement32% (44 patients)14.1 ± 14.7 h(0 – 72 h)5% (7 patients)83% at 3 years165% at 3 years———86% at 1 year92% at 2 years85% at 3 years194% at 1 year185% at 2 years179% at 3 years———69% at 1 year74% at 2 years76% at 3 years124% at 1 year145% at 2 years139% at 3 yearsDURABILITYQOL: score% Improvement79% at 3 years——PVR: mL % Improvement71% at 3 years——Complications% ObservedHaematuria8.6% (12 patients)Dysuria9.4% (13 patients)Bladder NeckContracture1.4% (2 patients)Urethral Stricture0.7% (1 patients)Re-treatment4.3% (6 patients)Blood Transfusion0Transient UrgeIncontinence6.5% (9 patients)UTI2.2% (3 patients)Epididymitis0.7% (1 patient)Erectile Dysfunction0Intraoperative FluidAbsorption0
Page 1 and 2: 151557_GreenLightSummary_B 5/31/07
Page 5: 151557_GreenLightSummary_B 5/31/07

C L I N I C A L S T U D Y S U M M A R Y

Create successful ePaper yourself

Delete template?

Save as template?